South Africa strengthens HIV prevention with Lenacapavir

Africa, Health, Uncategorized

PRETORIA, SOUTH AFRICA, 8 April 2026 (NPA) — The South African Government has received its first consignment of 37,920 doses of Lenacapavir, a groundbreaking long-acting injectable that offers up to six months of protection against HIV with just two injections per year.

This milestone marks a significant advance in the country’s HIV response, expanding prevention options particularly for adolescent girls, young women, sex workers, and men who have sex with men. The introduction of Lenacapavir is expected to accelerate efforts to reduce new HIV infections and support South Africa’s goal of ending AIDS as a public health threat by 2030.

Lenacapavir is not a vaccine but a long-acting HIV prevention medicine. Administered twice yearly, it provides continuous protection and offers a convenient alternative for individuals who face challenges with existing prevention methods.

The Government emphasised that the rollout of Lenacapavir strengthens its integrated, people-centred approach to HIV prevention. The six-monthly injectable is expected to improve adherence and expand choices for high-risk populations.

An official launch will be announced in the coming weeks, including details of a phased implementation plan to ensure effective and equitable distribution across the country.